Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 2;14(1):275.
doi: 10.1186/s13023-019-1211-5.

Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review

Affiliations
Review

Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review

Małgorzata Kałużna et al. Orphanet J Rare Dis. .

Abstract

Background: Gaucher disease (GD) is one of the most prevalent lysosomal storage diseases and is associated with hormonal and metabolic abnormalities, including nutritional status disorders, hypermetabolic state with high resting energy expenditures, peripheral insulin resistance, hypoadiponectinaemia, leptin and ghrelin impairments, hypolipidaemia, linear growth deceleration and growth hormone deficiency, delayed puberty, hypocalcaemia and vitamin D deficiency. Specific treatments for GD such as enzyme replacement therapy and substrate reduction therapy display significant effects on the metabolic profile of GD patients. Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1. GD1 appears to facilitate the development of disorders of nutrition, glucose metabolism and vitamin D insufficiency. Metabolic and hormonal diseases may have a significant impact on the course of the underlying disease and patient quality of life.

Conclusions: Conditions relating to hormones and metabolism can be wide-ranging in GD1. Obtained findings were intrinsic to GD either as a deleterious process or a compensatory response and some changes detected may represent co-morbidities. Actively seeking and diagnosing endocrine and metabolic disorders are strongly recommended in GD1 patients to optimize healthcare.

Keywords: Adpionectin; Delayed puberty; Dyslipidaemia; Gaucher disease (GD); Growth hormone deficiency; Insulin resistance; Leptin; Malnutrition; Obesity; Vitamin D deficiency.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372(9645):1263–1271. doi: 10.1016/S0140-6736(08)61522-6. - DOI - PubMed
    1. Tylki-Szymanska A, Czartoryska B, Vanier MT, Poorthuis BJ, Groener JA, Lugowska A, et al. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet. 2007;72(6):538–542. doi: 10.1111/j.1399-0004.2007.00899.x. - DOI - PubMed
    1. Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, et al. Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci. 2012;117(1):28–34. doi: 10.3109/03009734.2011.641609. - DOI - PMC - PubMed
    1. Machaczka M, Kampe Bjorkvall C, Wieremiejczyk J, Paucar Arce M, Myhr-Eriksson K, Klimkowska M, et al. Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3. Arch Immunol Ther Exp (Warsz) 2015;63(1):65–71. doi: 10.1007/s00005-014-0308-8. - DOI - PMC - PubMed
    1. Sawicka-Gutaj N, Machaczka M, Kulinska-Niedziela I, Bernardczyk-Meller J, Gutaj P, Sowinski J, et al. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy. Ups J Med Sci. 2016;121(3):192–195. doi: 10.3109/03009734.2016.1158756. - DOI - PMC - PubMed

Publication types

MeSH terms